Previous close | 30.05 |
Open | 30.20 |
Bid | N/A x N/A |
Ask | N/A x N/A |
Day's range | 30.20 - 30.50 |
52-week range | 29.95 - 40.48 |
Volume | |
Avg. volume | 2,590,169 |
Market cap | 195.903B |
Beta (5Y monthly) | 0.15 |
PE ratio (TTM) | 15.52 |
EPS (TTM) | N/A |
Earnings date | N/A |
Forward dividend & yield | 1.39 (4.58%) |
Ex-dividend date | 14 Mar 2024 |
1y target est | N/A |
Roche (RHHBY) has won FDA approval for Alecensa as an adjuvant treatment, following tumor resection for patients with ALK-positive non-small cell lung cancer.
J&J (JNJ) posts mixed first-quarter 2024 results. Lilly's (LLY) tirzepatide meets key goals in late-stage studies for obstructive sleep apnea.
Adaptimmune's (ADAP) shares plummet as the company;s collaboration to develop and commercialize allogeneic cell therapies with Roche gets terminated.